ADELPHI, Md. - An FDA panel Thursday said the benefits of Theratechnologies Inc.'s Egrifta (tesamorelin acetate) in reducing excess abdominal fat in HIV-infected patients with lipodystrophy outweighed the drug's potential risks of diabetes and cancer. (BioWorld Today)

Clovis Oncology Inc. has landed a second oncology partnership in its first year of business, this time with Waltham, Mass.-based Avila Therapeutics Inc. to develop and commercialize epidermal growth factor receptor (EGFR) mutant-selective inhibitors (EMSI) to treat non-small-cell lung cancer (NSCLC) in a deal potentially worth $209 million. (BioWorld Today)